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with HIV. However, granulomatous reactions, 
lymphocytic infiltration, and elevated levels of 
CSF proinflammatory cytokines have been de-
scribed.1,2 The degree of inflammation in patients 
who are receiving HAART is unknown but is 
probably higher than in patients who are not 
receiving HAART. Our trial was designed to aid 
decision making at the point of diagnosis. A total 
of 40% of the patients in our trial were receiving 
HAART at trial entry. However, we found no 
benefit of dexamethasone, even in this pre-
defined subgroup analysis. As Miller notes, IRIS 
occurred infrequently in both trial groups by 
6 months (in 6 of 226 patients in the placebo 
group and in 7 of 224 patients in the dexameth-
asone group). The low rate of IRIS is interesting; 
we speculate that it was due to the use of higher 
doses of antifungal agents (particularly flucona-
zole) than were typically used in previous cohorts.
Brandt questions the appropriateness of the 
regimen chosen. We chose the lowest dexametha-
sone dose used in the trial involving patients with 
tuberculous meningitis reported on by Thwaites 
et al. because in that trial patients who received 
active drug had fewer serious adverse events than 
patients who received placebo.3 Among the pa-
tients in the trial by Thwaites et al., 18% were 
infected with HIV and most had profound im-
munosuppression; no evidence of harm was seen.
Survival in relation to the Glasgow Coma Scale 
score at admission is provided in Table 2 of our 
article, and survival in relation to raised intracra-
nial pressure is described in Section 10 of the 
Supplementary Appendix (available with the full 
text of our article at NEJM.org). We think that all-
cause mortality is the most clinically meaningful 
end point and that our conclusions are robust.
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Amoxicillin for Severe Acute Malnutrition in Children
To the Editor: Isanaka and colleagues (Feb. 4 
issue)1 report the results of a double-blind, place-
bo-controlled trial that showed no benefit from 
the routine use of amoxicillin in a cohort of chil-
dren with uncomplicated severe malnutrition in 
Niger. The authors conclude that amoxicillin may 
not have a place in the empirical management of 
uncomplicated severe malnutrition in developing 
countries. We strongly support the view that an-
tibacterial chemotherapy is not a magic bullet, 
and we wish to highlight the potential unintend-
ed consequences of the mass use of antibacterial 
agents in this context, including the potential for 
drug resistance. With the World Health Organi-
zation giving a central role to amoxicillin in its 
essential medicines list,2 and recent data con-
firming that the use of antimicrobial agents in 
childhood is associated with long-lasting shifts 
in the intestinal microbiome,3 we call for a shift 
of emphasis away from the mass administration 
of antibacterial agents. Instead, ensuring that es-
sential antibacterial agents for the treatment of 
clinical infections are accessible for all, while 
sustaining their effectiveness, must remain cen-
tral to our global approach to managing infec-
tions — now and for generations to come.4
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To the Editor: Isanaka et al. conducted a trial 
involving only a subgroup of children who meet 
the case definition of severe acute malnutrition, 
excluding those with kwashiorkor.1,2 As two man-
ifestations of severe acute malnutrition, maras-
mus and kwashiorkor are typically treated with 
the same therapeutic regimen.3 The availability 
of physicians and the high rate of transfers to 
inpatient care do not reflect operational condi-
tions, limiting generalizability. The censoring of 
outcomes at the time of recommendation for 
hospitalization, even though half the children 
with such a recommendation were not actually 
admitted, skews the results toward a failure of 
therapy. We disagree that the routine use of anti-
biotic agents is unnecessary in children with ma-
rasmus. Finding no significant benefit is quite 
different from asserting that there is no benefit, 
especially when the lower boundary of the 95% 
confidence interval for a benefit with amoxicillin 
is 0.99. The direction and magnitude of their re-
sults are fully consistent with a previous trial 
conducted in Malawi,4 which also showed a trend 
toward higher rates of recovery among children 
with marasmus who were treated with amoxicil-
lin. Combining the results of these trials shows 
that 946 of 1396 children (67.8%) who were treat-
ed with amoxicillin recovered, as compared with 
897 of 1395 (64.3%) who received placebo (risk 
ratio, 1.08; 95% confidence interval [CI], 1.00 to 
1.37; P = 0.05 by Mantel–Haenszel analysis).
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The authors reply: Rawson et al. highlight the 
importance of antibiotic stewardship, and we 
agree that the prudent use of existing antibiotics 
is essential to sustain their long-term effective-
ness. Although Trehan and colleagues conducted 
a trial in Malawi1 that was similar to ours, we 
disagree on all three points. First, although our 
trial included only children with marasmus, we 
do not agree that this represents only a subgroup 
of children who meet the case definition of severe 
acute malnutrition. The comprehensive analysis 
of 852 nutritional surveys,2 also cited by Trehan 
et al., confirms that the overall burden of severe 
acute malnutrition differs little with the exclusion 
of edema and substantiates the conclusion that 
marasmic severe acute malnutrition represents 
the preponderance of cases worldwide. In Niger, 
1% of the children who were screened for eligi-
bility in our trial were excluded owing to kwash-
iorkor (Fig. 1 of our article), which similarly sug-
gests a minimal consequence of the exclusion on 
the overall generalizability of the trial findings.
Second, we disagree that the discontinuation 
of follow-up at the time of transfer to inpatient 
care represents a “censoring of outcomes.” In our 
trial, the secondary outcome under evaluation 
was first transfer to inpatient care. Discontinua-
tion of follow-up at this moment is therefore not 
informative censoring that produces bias; rather, 
it is a result of achieving an outcome of clinical 
and programmatic interest as intended in our 
protocol. Third, we appreciate the importance of 
considering effect size, boundaries of confidence 
intervals, and significance levels,3 but we main-
tain the interpretation of our findings that a 
benefit of routine amoxicillin in terms of nutri-
tional recovery was not confirmed in our trial. 
The pooled analysis presented by Trehan et al. 
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confirms that there is no significant benefit 
(P<0.05) of routine amoxicillin with regard to 
recovery during treatment (risk ratio, 1.08; 95% 
CI, 1.00 to 1.37; P = 0.05). We do, however, agree 
on the challenges in generalizing research find-
ings to operational settings. This limitation was 
recognized in the article, and we are currently 
supporting efforts to confirm the research find-
ings in the context of a routine nutrition treatment 
program with Médecins sans Frontières in Niger.
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Eliminating Pediatric HIV-1 Infection
To the Editor: We agree with Luzuriaga and 
Mofenson (Feb. 25 issue)1 that it is possible to 
contemplate the elimination of mother-to-child 
transmission of human immunodeficiency virus 
type 1 (HIV-1) in the United States and in re-
source-limited areas. To that end, the framework 
at the Centers for Disease Control and Prevention 
(CDC) for the elimination of mother-to-child 
transmission of HIV-1 in the United States uses 
two targets: an incidence of less than 1 case per 
100,000 live births and a mother-to-child trans-
mission rate of less than 1%.2 Regarding the rate 
of less than 1% that is attributed to the United 
States in the article, the authors cite data from 
the United Kingdom and Ireland.3
Lacking a regular determination of the num-
ber of HIV-infected women who deliver infants 
in the United States, the national rate of mother-
to-child transmission (2.2%) was last estimated 
with the use of the Enhanced Perinatal Surveil-
lance data from the CDC for the period 2005–
2008.4 The incidence of perinatal HIV-1 infection 
declined from 4.0 cases per 100,000 live births 
(in 2008) to 3.1 cases per 100,000 live births (in 
2012) but with striking disparities among racial 
and ethnic groups: the rate was 15.1 cases per 
100,000 live births among black infants, 1.7 per 
100,000 live births among Hispanic infants, and 
0.3 per 100,000 live births among white infants 
(Fig. 1).5 Before and after meeting the targets 
for the elimination of mother-to-child trans-
mission of HIV-1 for the United States as a 
whole, we must focus attention and resources 
on strategies to reduce the high rates of peri-
natal HIV infection in racial and ethnic minor-
ity populations.
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Figure 1. Rate of Perinatally Acquired HIV Infection, According to Year  
of Birth and Maternal Race or Ethnic Group, 2008–2012.
HIV denotes human immunodeficiency virus.
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